BOJI CRO(SZ:300404) Zheng Quan Zhi Xing·2025-08-26 16:40Core Viewpoint - The legal opinion issued by Beijing Kangda Law Firm confirms the validity and compliance of the stock incentive plan of Boji Pharmaceutical Technology Co., Ltd, particularly regarding the cancellation of certain restricted stocks [1][12]. Group 1: Legal Compliance and Verification - The law firm conducted thorough verification and confirmed that all provided documents and statements from Boji Pharmaceutical were authentic and accurate [2][3]. - The legal opinion is strictly focused on legal issues related to the incentive plan and does not cover accounting, financial, or auditing matters [2][3]. Group 2: Stock Incentive Plan Details - The company approved the 2023 restricted stock incentive plan, granting a total of 2,968,000 shares to 47 eligible participants, with the first grant date set for April 26, 2023 [3][4]. - The first category of restricted stocks was granted at a price of 5.47 CNY per share, while the second category was granted at 8.75 CNY per share [3][4]. - Adjustments were made to the grant prices following the annual profit distribution, reducing the first category price to 5.46 CNY and the second category price to 8.74 CNY [4][7]. Group 3: Cancellation of Restricted Stocks - The company decided to cancel 140,600 shares of the second category of restricted stocks due to certain participants failing to meet performance criteria or leaving the company [5][10]. - An additional 300,000 shares from the reserved portion of the second category were also rendered invalid due to not being granted within the stipulated timeframe [5][10]. - The legal opinion asserts that the cancellation of these stocks has received the necessary approvals and complies with relevant regulations [11][12].